The abstract is read at the publisher; the summary is JClub's.
Nirsevimab reduced RSV hospitalization risk by 95% (95% CI: 84% to 98%) and medically-attended RSV by 67% (95% CI: 45% to 80%) through 180 days post-receipt in 4,826 infants.
- Why it matters: Prior real-world estimates rely on test-negative designs that restrict to healthcare-seeking and testing populations, limiting generalizability beyond those who get tested.
- What they did: Using a target trial emulation with g-computation and Cox models, investigators estimated 30-day interval cumulative incidence of RSV hospitalization and medically-attended RSV through 180 days post-receipt in infants at Kaiser Permanente Georgia.
- The result: The number needed to immunize was 147 (95% CI: 94 to 333) for RSV hospitalization and 39 (95% CI: 28 to 68) for medically-attended RSV, supporting effectiveness through 180 days post-receipt.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.